Anti‐interleukin‐6 signalling therapy rebalances the disrupted cytokine production of B cells from patients with active rheumatoid arthritis
- 27 September 2017
- journal article
- research article
- Published by Wiley in European Journal of Immunology
- Vol. 48 (1) , 194-203
Abstract
Rheumatoid arthritis (RA) is associated with abnormal B cell‐functions implicating antibody‐dependent and ‐independent mechanisms. B cells have emerged as important cytokine‐producing cells, and cytokines are well‐known drivers of RA pathogenesis. To identify novel cytokine‐mediated B‐cell functions in RA, we comprehensively analysed the capacity of B cells from RA patients with an inadequate response to disease modifying anti‐rheumatic drugs to produce cytokines in comparison with healthy donors (HD). RA B cells displayed a constitutively higher production of the pathogenic factors interleukin (IL)‐8 and Gro‐α, while their production of several cytokines upon activation via the B cell receptor for antigen (BCR) was broadly suppressed, including a loss of the expression of the protective factor TRAIL, compared to HD B cells. These defects were partly erased after treatment with the IL‐6‐signalling inhibitor tocilizumab, indicating that abnormal IL‐6 signalling contributed to these abnormalities. Noteworthy, the clinical response of individual patients to tocilizumab therapy could be predicted using the amounts of MIP‐1β and β‐NGF produced by these patients’ B cells before treatment. Taken together, our study highlights hitherto unknown abnormal B‐cell functions in RA patients, which are related to the unbalanced cytokine network, and are potentially relevant for RA pathogenesis and treatment.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (TRR130, SFB650, 491/7‐3)
This publication has 36 references indexed in Scilit:
- Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritisAnnals of the Rheumatic Diseases, 2013
- B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6–producing B cellsJournal of Experimental Medicine, 2012
- Permutation P-values Should Never Be Zero: Calculating Exact P-values When Permutations Are Randomly DrawnStatistical Applications in Genetics and Molecular Biology, 2010
- Baseline Serum Concentrations of TRAIL in Early Rheumatoid Arthritis: Relationship with Response to Disease-modifying Antirheumatic DrugsThe Journal of Rheumatology, 2010
- Elevated expression of caspase-3 inhibitors, survivin and xIAP correlates with low levels of apoptosis in active rheumatoid synoviumArthritis Research & Therapy, 2009
- Is there any role for tumour necrosis factor related apoptosis inducing ligand–osteoprotegerin (TRAIL–OPG) interaction in rheumatoid arthritis?Annals of the Rheumatic Diseases, 2008
- Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trialThe Lancet, 2008
- The effect of infliximab on chemokines in patients with rheumatoid arthritisClinical Rheumatology, 2006
- A Lego System for Conditional InferenceThe American Statistician, 2006
- Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor αArthritis & Rheumatism, 1993